Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
255 hedge funds and large institutions have $4.15B invested in Clovis Oncology, Inc. in 2017 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 118 increasing their positions, 63 reducing their positions, and 55 closing their positions.
87% more repeat investments, than reductions
Existing positions increased: 118 | Existing positions reduced: 63
69% more call options, than puts
Call options by funds: $178M | Put options by funds: $105M
6% less funds holding
Funds holding: 271 → 255 (-16)
9% less capital invested
Capital invested by funds: $4.57B → $4.15B (-$412M)
22% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 55
44% less funds holding in top 10
Funds holding in top 10: 16 → 9 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$51.6M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$51.1M |
| 3 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$46.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$42.3M |
| 5 |
HM
HealthCor Management
New York
|
+$31.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$69.6M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$58.2M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$57.1M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$54M |
| 5 |
CCM
Consonance Capital Management
New York
|
-$51M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
301
Squarepoint
New York
| – | -$253K | -2,700 | Closed |
|
|
BFM
302
Boothbay Fund Management
New York
| – | -$204K | -2,567 | Closed |
|
|
LCM
303
Legato Capital Management
San Francisco,
California
| – | -$220K | -2,346 | Closed |
|
|
PAM
304
Paradigm Asset Management
New York
| – | -$84.3K | -900 | Closed |
|
|
MAM
305
Meeder Asset Management
Dublin,
Ohio
| – | -$29K | -309 | Closed |
|
|
CSS
306
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$12K | -133 | Closed |
|
|
CHP
307
Cable Hill Partners
Portland,
Oregon
| – | -$12K | -125 | Closed |
|
308
Acadian Asset Management
Boston,
Massachusetts
| – | -$4K | -43 | Closed |
|
|
AA
309
AlphaMark Advisors
Ft. Wright,
Kentucky
| – | -$1K | -12 | Closed |
|
|
PHK
310
Point72 Hong Kong
Hong Kong
| – | -$1K | -7 | Closed |
|
CLVS Hedge Fund Activity: Q3 2017 in Review
255 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q3 2017, worth a combined $4.15B — down 9% from $4.57B a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of CLVS and 43 opened new positions — a net loss of 12 holders — while 63 trimmed existing stakes and 118 added.
The largest buyer was Franklin Resources, adding an estimated $51.6M. The largest seller was D.E. Shaw & Co, cutting an estimated $69.6M.
- 255 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q3 2017, down from 271 in Q2 2017.
- Funds reported $4.15B of Clovis Oncology, Inc. stock for Q3 2017, down 9% quarter-over-quarter.
- 43 funds opened new Clovis Oncology, Inc. positions in Q3 2017 and 55 closed out, a net change of -12 holders.
- The largest Clovis Oncology, Inc. buyer in Q3 2017 was Franklin Resources, an estimated $51.6M added.
- The largest Clovis Oncology, Inc. seller in Q3 2017 was D.E. Shaw & Co, an estimated $69.6M sold.
Based on aggregated 13F filings for Q3 2017.